4//SEC Filing
Mulay James 4
Accession 0001193125-25-210015
CIK 0001991792other
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 7:30 AM ET
Size
13.4 KB
Accession
0001193125-25-210015
Insider Transaction Report
Form 4
Mulay James
Director
Transactions
- Exercise/Conversion
Common Stock
2025-09-19$1.82/sh+3,574$6,505→ 3,574 total - Exercise/Conversion
Director Stock Option (right to buy)
2025-09-18−19,112→ 16,329 totalExercise: $1.82Exp: 2031-07-18→ Common Stock (19,112 underlying) - Exercise/Conversion
Common Stock
2025-09-18$1.82/sh+19,112$34,784→ 19,112 total - Sale
Common Stock
2025-09-18$39.01/sh−19,112$745,559→ 0 total - Sale
Common Stock
2025-09-19$38.99/sh−3,574$139,350→ 0 total - Exercise/Conversion
Director Stock Option (right to buy)
2025-09-19−3,574→ 12,755 totalExercise: $1.82Exp: 2031-07-18→ Common Stock (3,574 underlying)
Footnotes (3)
- [F1]The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.99 to $39.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Fully vested
Documents
Issuer
CG Oncology, Inc.
CIK 0001991792
Entity typeother
Related Parties
1- filerCIK 0001684531
Filing Metadata
- Form type
- 4
- Filed
- Sep 21, 8:00 PM ET
- Accepted
- Sep 22, 7:30 AM ET
- Size
- 13.4 KB